A phase 3 study puts faster-onset botulinum toxin E back into the glabellar-line conversation.
A placebo-controlled phase 3 study published July 24, 2026 found trenibotulinumtoxinE improved moderate-to-severe glabellar lines quickly, with effects observed at hour 8, peaking at day 7 and largely returning by day 21. The study is about rapid onset and short duration in a controlled setting, not proof that a shorter-acting toxin is the right fit for every forehead or frown-line plan.
Reviewed for the Dagan Edit
Share quietly
Renaissance-style neuromodulator study representing glabellar-line treatment planning; not an actual patient result
The report, in context
What this development means—and what it does not.
A placebo-controlled phase 3 study published July 24, 2026 found trenibotulinumtoxinE improved moderate-to-severe glabellar lines quickly, with effects observed at hour 8, peaking at day 7 and largely returning by day 21. The study is about rapid onset and short duration in a controlled setting, not proof that a shorter-acting toxin is the right fit for every forehead or frown-line plan.
Inclusion is not an endorsement; treatment suitability, product safety and postoperative care require individualized guidance from a qualified clinician.
Madison Avenue · New York City
Bring the question into a clinical conversation.
A consultation connects general educational context to an individual examination, reasonable options, limitations, and recovery.
